Hideki Garren

9.9k total citations · 2 hit papers
59 papers, 4.6k citations indexed

About

Hideki Garren is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Hideki Garren has authored 59 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pathology and Forensic Medicine, 25 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in Hideki Garren's work include Multiple Sclerosis Research Studies (27 papers), Immunotherapy and Immune Responses (15 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Hideki Garren is often cited by papers focused on Multiple Sclerosis Research Studies (27 papers), Immunotherapy and Immune Responses (15 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Hideki Garren collaborates with scholars based in United States, Switzerland and Canada. Hideki Garren's co-authors include Lawrence Steinman, Benjamin Cheyette, S Lawrence Zipursky, Paulo Fontoura, Annette Langer‐Gould, Rosetta Pedotti, Stephen J. Galli, Christopher Lock, K. Martin and Volker Hartenstein and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Hideki Garren

57 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

2002 1.4k citations Christopher Lock, G Hermans et al. Nature Medicine profile →
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

2020 317 citations Anthony Traboulsee, Hideki Garren et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideki Garren United States	28	1.9k	1.4k	1.3k	552	527	59	4.6k
Barbara Cannella United States	19	2.5k 1.3×	1.1k 0.8×	1.9k 1.4×	554 1.0×	331 0.6×	28	4.9k
Gregory P. Owens United States	37	1.4k 0.7×	950 0.7×	1.9k 1.4×	1.1k 1.9×	293 0.6×	68	3.8k
Maria K. Storch Austria	33	1.6k 0.8×	1.2k 0.9×	2.9k 2.2×	1.4k 2.5×	582 1.1×	55	5.0k
Monika Bradl Austria	40	1.8k 0.9×	1.6k 1.1×	2.8k 2.2×	1.6k 2.8×	584 1.1×	75	6.1k
Wolfgang E. F. Klinkert Germany	25	1.4k 0.7×	1.3k 0.9×	660 0.5×	302 0.5×	845 1.6×	33	4.5k
Francesca Odoardi Germany	24	1.2k 0.6×	630 0.4×	581 0.4×	261 0.5×	295 0.6×	39	2.9k
Helene Breitschopf Austria	18	666 0.3×	1.1k 0.8×	557 0.4×	281 0.5×	443 0.8×	21	2.7k
Manfred Schmidbauer Austria	22	754 0.4×	1.1k 0.8×	3.3k 2.5×	1.3k 2.3×	493 0.9×	48	5.2k
Takayuki Harada Japan	42	596 0.3×	3.5k 2.4×	259 0.2×	412 0.7×	1.4k 2.7×	197	5.9k
Yasuyuki Ohkawa Japan	48	979 0.5×	5.1k 3.6×	878 0.7×	133 0.2×	684 1.3×	214	7.6k

Countries citing papers authored by Hideki Garren

Since Specialization

Citations

This map shows the geographic impact of Hideki Garren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Garren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Garren more than expected).

Fields of papers citing papers by Hideki Garren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Garren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Garren. The network helps show where Hideki Garren may publish in the future.

Co-authorship network of co-authors of Hideki Garren

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Garren. A scholar is included among the top collaborators of Hideki Garren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Garren. Hideki Garren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martényi, Ferenc, Brian Campbell, Gene G. Kinney, et al.. (2023). PRX005, a novel anti‐MTBR tau monoclonal antibody: results from a first‐in‐human double‐blind, placebo‐controlled, single ascending dose phase 1 study. Alzheimer s & Dementia. 19(S21). 4 indexed citations

Traboulsee, Anthony, Stephen L. Hauser, Eva Havrdová, et al.. (2017). Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies (P6.338). Neurology. 88(16_supplement). 1 indexed citations

Wolinsky, Jerry S., Xavier Montalbán, Ludwig Kappos, et al.. (2017). Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384). Neurology. 88(16_supplement). 1 indexed citations

Arnold, Douglas L., Amit Bar‐Or, Giancarlo Comi, et al.. (2016). Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002). Neurology. 86(16_supplement). 1 indexed citations

Traboulsee, Anthony, Douglas L. Arnold, Amit Bar‐Or, et al.. (2016). Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004). Neurology. 86(16_supplement). 12 indexed citations

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. mediaTUM (Technical University of Munich). 36 indexed citations

Hauser, Stephen L., Gıancarlo Comı, Hans‐Peter Hartung, et al.. (2015). Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201). Neurology. 84(14_supplement). 3 indexed citations

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017). Neurology. 84(14_supplement). 2 indexed citations

Roep, Bart O., Nanette Solvason, Peter A. Gottlieb, et al.. (2013). Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 ⁺ T Cells in Type 1 Diabetes. Science Translational Medicine. 5(191). 191ra82–191ra82. 127 indexed citations

10.

Papadopoulou, Athina, Stefanie von Felten, Amena Rahman, et al.. (2012). Evolution of MS lesions to black holes under DNA vaccine treatment. Journal of Neurology. 259(7). 1375–1382. 15 indexed citations

11.

Garren, Hideki. (2009). DNA vaccines for autoimmune diseases. Expert Review of Vaccines. 8(9). 1195–1203. 18 indexed citations

12.

Fontoura, Paulo & Hideki Garren. (2009). Multiple Sclerosis Therapies: Molecular Mechanisms and Future. Results and problems in cell differentiation. 51. 259–285. 16 indexed citations

13.

Platten, Michael, Peggy P. Ho, Sawsan Youssef, et al.. (2005). Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite. Science. 310(5749). 850–855. 350 indexed citations

14.

Ho, Peggy P., Paulo Fontoura, Michael Platten, et al.. (2005). A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease. The Journal of Immunology. 175(9). 6226–6234. 47 indexed citations

15.

Fontoura, Paulo, Peggy P. Ho, Jason DeVoss, et al.. (2004). Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 173(11). 6981–6992. 51 indexed citations

16.

Ho, Peggy P., Paulo Fontoura, Pedro Ruiz, Lawrence Steinman, & Hideki Garren. (2003). An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems. The Journal of Immunology. 171(9). 4920–4926. 69 indexed citations

17.

Lock, Christopher, G Hermans, Rosetta Pedotti, et al.. (2002). Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Medicine. 8(5). 500–508. 1355 indexed citations breakdown →

18.

Cheyette, Benjamin, et al.. (1994). The drosophila sine oculis locus encodes a homeodomain-containing protein required for the development of the entire visual system. Neuron. 12(5). 977–996. 439 indexed citations

19.

Ebens, Allen, Hideki Garren, Benjamin Cheyette, & S Lawrence Zipursky. (1993). The Drosophila anachronism locus: A glycoprotein secreted by glia inhibits neuroblast proliferation. Cell. 74(1). 15–27. 174 indexed citations

20.

DeYoe, Edgar A., Susan Hockfield, Hideki Garren, & David C. Van Essen. (1990). Antibody labeling of functional subdivisions in visual cortex: Cat-301 immunoreactivity in striate and extrastriate cortex of the macaque monkey. Visual Neuroscience. 5(1). 67–81. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact